Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
If you wanted proof that technology always gets smaller then here it is, and in this case it could revolutionist patient diagnostics.
Over time everyone knows that advances in technology help us turn big things into littler things – like digital cameras that used to be the size of a briefcase but that now are small enough to travel around your bloodstream scanning you from the inside, or fitting the ginormous CERN particle accelerator onto a tiny chip … And now one of the biggest pieces of advanced tech on the planet, Magnetic Resonance Imaging (MRI) machines, which cost millions of dollars each and, up until recently, occupied a whole hospital room, are getting the same miniaturisation treatment after a new breakthrough.
Decades after MRI machines first broke onto the scene, and before magnetic wormholes one day possibly help us realise a world where people can get an MRI scan just by walking around an empty room, the world’s first portable MRI machine has just been used to help detect brain abnormalities in patients by the bedside.
Developed by healthcare technology company Hyperfine in the US, the point-of-care (POC) MRI system was first revealed last year, and the manufacturers claim that it’s 20 times cheaper, uses 35 times less power, and is 10 times lighter than its larger cousins.
Traditional MRI machines are big and expensive devices, requiring custom-built rooms to contain the powerful magnetic fields used for imaging. Until recently, the prospect of a portable MRI machine was unimaginable but recent advances in computing power have enabled images to be produced using smaller magnets.
The magnetic fields used in MRI machines are tracked with a unit of measurement called a Tesla (T) – not the car company. Most current MRI machines rely on powerful magnets ranging from 1.5 T to 3 T. Hyperfine’s new POC machine uses a significantly smaller magnet of just 0.064 T.
This means the device can be easily rolled up to a patient’s bedside without deploying any protective measures in the surrounding environment. The machine also uses less electricity than large MRI machines, allowing it to be powered from a standard wall outlet.
In this new study, researchers from Yale Medicine tested the efficacy of the new MRI device in 30 patients admitted to Yale New Haven Hospital’s neuroscience intensive care unit. The new device detected a variety of abnormalities, ranging from brain tumors to ischemic stroke, in 29 of the patients.
The study also took the opportunity to study the neurological effects of COVID-19 in 20 patients admitted to intensive care. The nature of severe COVID-19 means these patients are generally unable to be transported to larger MRI rooms for imaging, so this proof-of-concept analysis suggests the portability of the POC device allows for many more patients to be investigated. Eight out of the 20 COVID-19 patients imaged showed acute neurological abnormalities associated with the disease.
More testing is necessary before the device is commercially rolled out into clinical environments and further studies will need to directly compare these POC MRI results to conventional MRI or CT imaging results. However, Hyperfine is clear in stating this new device is not designed to be a replacement for traditional high-field MRI imaging, but instead is intended to complement those diagnostic tools.
If effectively validated in further tests this portable MRI machine offers profound new diagnostic opportunities for clinicians. In intensive care situations the machine allows for fast assessment of neurological injuries and the novel ability to gather serial measurements introducing temporal imaging profiles of the same patient over several days or weeks.
The mobility of the device also allows for better diagnostics in rural or remote environments. The developers even hypothesize the machine could be integrated into ambulances for mobile patient assessments. This could potentially offer paramedics the ability to immediately diagnose stroke symptoms before a patient even gets to a hospital.
Speaking to STATNews last year, Hyperfine’s chief medical officer John Martin suggested the machine opens up incredible possibilities that could never have been considered, even a few short years ago.
“Now, the cool thing is that when you get this in front of doctors, they look at it, they start thinking about all kinds of creative ways in which they can use that,” Martin said in 2019. “You know, the thought of this now being in a van floating around Africa, that’s a mind-blowing concept, no one would ever dream of that at all. That’s actually possible now.” And, needless to say, that’s an awesome prospect
The new study was published in the journal JAMA Neurology.
Source: Yale News